Eisai Seeks To Launch ‘Blockbuster' Cancer Drug In Singapore
This article was originally published in PharmAsia News
Executive SummaryEisai said it has chosen Singapore to apply for its first approval in the Asia-Pacific region for its E7389 (synthetic halichondrin B), a blockbuster candidate for treating breast cancer. Eisai, which also plans to apply for approval at home, in Europe and the United States early next year, has the compound in trials for treating non-small-cell lung and prostate cancers as well as breast cancer. Eisai created the compound that controls the proliferation of cancer cells. (Click here for more - a subscription may be required
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.